A Phase 1 / 2, Open Label, Study of Amivantamab (JNJ-61186372) Among Participants with Advanced NSCLC Harboring ALK, ROS1, and RET Gene Fusions in Combination with Tyrosine Kinase Inhibitors

Is this Study for You?

Let's Get Started!

Details
Age

Adult

Type of Study

Treatment

Locations

Outpatient CTRC
University of Colorado Hospital
University of Michigan

Principal Investigator
Photograph of Tejas Patil,  MD

Tejas Patil, MD

Study ID

Protocol Number: 22-1450

More information available at ClinicalTrials.gov: NCT05845671

Categories

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers